Erythropoiesis-stimulating agent use among non-dialysis-dependent ckd patients before and after the trial to reduce cardiovascular events with Aranesp therapy (TREAT) using a large us health plan database

American Journal of Kidney Diseases

Volumn 64, Issue 5, 2014, Pages 706-713

  Thamer, Mae ^a   Zhang, Yi ^a   Kshirsagar, Onkar ^a   Cotter, Dennis J ^a   Kaufman, James S ^b  

^a Med Technol Pract Patterns Inst   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Choose Wisely campaign; darbepoetin predialysis chronic kidney disease (CKD); epoetin (EPO); hemoglobin anemia; Index Words Erythropoietin stimulating agent (ESA); MarketScan; prescribing patterns; Thomson Reuters; TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy)

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DATA BASE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRESCRIPTION; PUBLICATION; RETROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG EFFECTS; EPIDEMIOLOGY; ERYTHROPOIESIS; FACTUAL DATABASE; HEALTH INSURANCE; MEDICARE; MIDDLE AGED; PHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME; TRENDS; UNITED STATES;

AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; DATABASES, FACTUAL; ERYTHROPOIESIS; ERYTHROPOIETIN; FEMALE; FOR-PROFIT INSURANCE PLANS; HUMANS; MALE; MEDICARE; MIDDLE AGED; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 84908490949     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.05.013     Document Type: Article

References (23)

1. M.A. Pfeffer, E.A. Burdmann, and C.Y. Chen A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 361 21 2009 2019 2032
2. A.K. Singh Lessons from TREAT: lower hemoglobin target, avoid ESA if possible Nephrol Times 2 12 2009 6 7
3. A.K. Singh Diabetes, anemia and CKD: why TREAT? Curr Diabetes Rep 10 4 2010 291 296
4. FDA. FDA drug safety communication: modified dosing recommendations to improve the safe use of erythropoiesis-stimulating agents in chronic kidney disease. 2011. http://www.fda.gov/Drugs/DrugSafety/ucm259639.htm. Accessed April 12, 2013.
5. A.W. Williams, A.C. Dwyer, and A.A. Eddy Critical and honest conversations: the evidence behind the "Choosing Wisely" campaign recommendations by the American Society of Nephrology Clin J Am Soc Nephrol 7 10 2012 1664 1672
6. J.G. van Manen, J.C. Korevaar, and F.W. Dekker How to adjust for comorbidity in survival studies in ESRD patients: a comparison of different indices Am J Kidney Dis 40 1 2002 82 89
7. A.K. Singh Does TREAT give the boot to ESAs in the treatment of CKD anemia? J Am Soc Nephrol 21 1 2010 2 6
8. E.F. Unger, A.M. Thompson, M.J. Blank, and R. Temple Erythropoiesis-stimulating agents - time for a reevaluation N Engl J Med 362 3 2010 189 192
9. P.A. Marsden Treatment of anemia in chronic kidney disease - strategies based on evidence N Engl J Med 361 21 2009 2089 2090
10. D. Regidor, W.M. McClellan, R. Kewalramani, A. Sharma, and B.D. Bradbury Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009 Nephrol Dial Transplant 26 5 2011 1583 1591
11. A.K. Singh, L. Szczech, and K.L. Tang Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med 355 20 2006 2085 2098
12. T.B. Drueke, F. Locatelli, and N. Clyne Normalization of hemoglobin level in patients with chronic kidney disease and anemia N Engl J Med 355 20 2006 2071 2084
13. D.R. Dunn Dissemination of the published results of an important clinical trial: an analysis of the citing literature Bull Med Library Assoc 69 3 1981 301 306
14. D.A. Braunholtz, S.J. Edwards, and R.J. Lilford Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect." J Clin Epidemiol 54 3 2001 217 224
15. P.M. Rothwell External validity of randomised controlled trials: "to whom do the results of this trial apply?" Lancet 365 9453 2005 82 93
16. A.L. Dans, L.F. Dans, G.H. Guyatt, and S. Richardson Users' guides to the medical literature: XIV. How to decide on the applicability of clinical trial results to your patient. Evidence-Based Medicine Working Group JAMA 279 7 1998 545 549
17. M. Flather, N. Delahunty, and J. Collinson Generalizing results of randomized trials to clinical practice: reliability and cautions Clin Trials 3 6 2006 508 512
18. L.A. Green, and C.M. Seifert Translation of research into practice: why we can't "just do it." J Am Board Fam Pract 18 6 2005 541 545
19. H. Ludwig, and E. Fritz Anemia of cancer patients: patient selection and patient stratification for epoetin treatment Semin Oncol 25 3)(suppl 7 1998 35 38
20. H. Ludwig, E. Sundal, and M. Pecherstorfer Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy Cancer 76 11 1995 2319 2329
21. J.D. Rizzo, M. Brouwers, and P. Hurley American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer Blood 116 20 2010 4045 4059
22. A.J. Collins, H. Guo, D.T. Gilbertson, and B.D. Bradbury Predictors of ESA use in the non-dialysis chronic kidney disease population with anemia Nephron Clin Pract 111 2 2009 c141 c148
23. J. Siegel, J. Jorgenson, and P.E. Johnson Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings Am J Health Syst Pharm 65 18 2008 1711 1719